Compare Dow Jones Industrial Average ETF (DIA) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Inovio Pharmaceuticals Inc — how do they compare? Dow Jones Industrial Average ETF trades at $515.45 (market cap $45.20B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: Dow Jones Industrial Average ETF is far larger — about 402.9× Inovio Pharmaceuticals Inc's market cap, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 103 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DIA | INO | |
|---|---|---|
Market Cap | $45.20B | $112.19M |
Volume | 4,095,368 | 3,201,278 |
52-Week High | $542.79 | $2.65 |
52-Week Low | $451.37 | $0.66 |
Typical Hold Time | 103 Days | 43 Days |
Sector | — | Health |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA trades at $513.34, showing modest 0.45% daily gains amid bearish technical signals. The ETF faces selling pressure with moving averages indicating downward momentum while oscillators remain neutral. Recent dividend distributions provide income appeal, but key valuation metrics are unavailable for comprehensive fundamental assessment. Market sentiment reflects broader equity concerns as highlighted in recent financial coverage.
The outlook remains cautious given technical weakness and market volatility. Dividend payments offer income stability, but the absence of fundamental metrics limits valuation clarity. Key risks include broader market pressures and economic uncertainty, requiring careful monitoring of Dow Jones component performance for directional cues.
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
